Vertex to Announce First-Quarter 2021 Financial Results on April 29

Rhea-AI Summary

Vertex Pharmaceuticals (Nasdaq: VRTX) will announce its first-quarter 2021 financial results on April 29, 2021, after market close. A conference call will follow at 5:30 p.m. ET, accessible via dial-in and webcast on Vertex's website. Vertex is a leader in biotechnology, focusing on innovative treatments for serious diseases, particularly cystic fibrosis. The company also explores therapies for various other conditions, including sickle cell disease and type 1 diabetes. Vertex is recognized for its workplace culture and commitment to scientific advancement.

Positive

• Vertex has multiple approved treatments for cystic fibrosis.
• The company has ongoing clinical programs for serious diseases beyond cystic fibrosis.
• Vertex is recognized as a top employer in the biotechnology industry.

Negative

• None.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) – a rare, life-threatening genetic disease – and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005226/en/

FAQ

When will Vertex Pharmaceuticals release its first-quarter 2021 financial results?

Vertex Pharmaceuticals will report its first-quarter 2021 financial results on April 29, 2021, after the markets close.

What time is the conference call scheduled by Vertex Pharmaceuticals?

The conference call will be held at 5:30 p.m. ET on April 29, 2021.

How can I access the Vertex Pharmaceuticals conference call?

The conference call can be accessed by dialing (866) 501-1537 for U.S. callers or +1 (720) 545-0001 for international callers, and it will also be webcast live on Vertex's website.

What therapeutic areas does Vertex Pharmaceuticals focus on?

Vertex Pharmaceuticals focuses on treatments for cystic fibrosis and has a pipeline for other conditions such as sickle cell disease, type 1 diabetes, and muscular dystrophy.